The Gold Standard of Genetics | RNA Sequencing, Aberrant Splicing, Tissue Choice, Expression Outliers and Diagnostic Confirmation

THE GOLD STANDARD OF GENETICS · SPECIALIST STUDY

Use RNA sequencing to test a specific biological consequence, while keeping tissue, timing and confirmation visible

RNA sequencing can reveal consequences that DNA testing predicts but cannot directly observe: cryptic splice junctions, exon skipping, altered transcript abundance and allele-specific expression. It can also expose candidate genes when no single DNA variant is obvious. Yet RNA is conditional evidence. A gene may not be expressed in blood, a clinically accessible tissue may use different splice junctions from the affected organ, nonsense-mediated decay may remove the abnormal transcript, treatment or cell culture may alter expression, and a small or mismatched reference set may manufacture outliers. A responsible pathway begins with the clinical and molecular question, chooses tissue and collection timing deliberately, protects RNA integrity and identity, records library and sequencing properties, builds an appropriate reference cohort, examines expression, splicing and allelic imbalance together, links RNA events back to DNA and phenotype, confirms material findings with an orthogonal method where needed, and reports exactly what a negative result could not exclude.

This guide belongs to the Genetics subject root, the Gold Standard of Education, and the How X Works hub. It begins with a concrete decision, then tests whether the method still holds when the context changes.

The whole problem at a glance

Tissue choice is part of the test, not a detail after sequencing.

CHAPTER 2 OF 13 · Frame question and tissue

2. Choose tissue by expression and splice representation

Estimate whether the gene and relevant isoform are expressed and whether accessible tissue reproduces disease-relevant junctions; consider fibroblasts, muscle or induced cells when justified. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: Blood expresses the gene but not the neuronal exon under question, so a normal blood result is not used to exclude a brain-relevant splice defect. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: expression references; transcript models; tissue comparisons; disease organ; accessible alternatives; cell state; feasibility; residual limitation Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: High total gene expression does not guarantee that the relevant isoform or splice event is represented, and cultured cells can change transcription. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Keep the gene constant but switch from blood to fibroblasts and reassess informative junctions and reference controls. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

CHAPTER 4 OF 13 · Protect the specimen and assay

4. Protect identity, RNA integrity and pre-analytics

Trace the specimen and measure degradation, contamination, cell composition and processing delay before interpreting read counts. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: A low RNA integrity sample shows 3-prime bias and many apparent junction losses, so it fails the diagnostic acceptance gate. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: patient and sample IDs; consent; collection tube; delay; storage; extraction; RNA integrity; concentration; contamination; cell composition Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: Bioinformatics cannot restore transcript information lost before sequencing, and low-quality samples can produce structured false outliers. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Keep sequencing depth high but reduce RNA integrity and explain why coverage does not cure degradation bias. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

CHAPTER 6 OF 13 · Detect and connect outliers

6. Build a matched and versioned reference cohort

Use controls compatible in tissue, preparation, platform, ancestry where relevant, age or cell state, and batch; document how reference updates affect outlier scores. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: A patient sequenced in a new library batch is not compared naively with older controls until bridging shows that the batch shift is controlled. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: control eligibility; tissue; demographics; batch; platform; library; quality; size; update date; bridge analysis; exclusions Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: A large mismatched cohort can be worse than a smaller compatible one, and reference updates can change who is called an outlier. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Add fifty controls from a different tissue and show why sample size alone does not improve calibration. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

CHAPTER 8 OF 13 · Detect and connect outliers

8. Detect aberrant splicing at read and junction level

Inspect novel junctions, exon skipping, intron retention and alternative boundaries with read support, sequence uniqueness and transcript context. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: Reads support a cryptic donor near a DNA variant across replicates, while a low-complexity mapping alternative is explicitly rejected. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: junction counts; split reads; coverage; sequence uniqueness; transcript annotation; replicates; visual review; controls; effect size Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: One unusual read is not a validated splice event, and annotation absence does not make a junction disease-causing. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Shorten read length and determine whether the cryptic junction remains uniquely mappable. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

RNA evidence gate

The strongest result explains both the RNA observation and the person’s genetic and clinical context.

CHAPTER 10 OF 13 · Confirm and interpret

10. Account for nonsense-mediated decay and transcript rescue

Recognise that unstable abnormal transcripts may be depleted; where appropriate and validated, compare conditions or use complementary assays that reveal the hidden event. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: A premature-stop transcript is barely visible at baseline but its predicted splice junction is confirmed with a targeted assay designed around the event. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: variant position; transcript model; decay prediction; baseline reads; treatment or culture condition; targeted confirmation; safety and validation Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: Manipulating decay can change many transcripts and is not a routine proof by itself; absence of abnormal RNA may reflect successful degradation. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Keep the DNA variant fixed but move it to the last exon and reassess the decay expectation. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

CHAPTER 12 OF 13 · Report, reanalyse and transfer

12. Confirm material findings and integrate evidence

Use targeted RT-PCR, amplicon sequencing, Sanger sequencing, qPCR, long-read RNA or another suitable method where validation and clinical use require it, then apply the proper classification framework. Begin with one person, one diagnostic question, one tissue and collection condition, one RNA-seq assay, one reference cohort, one candidate event and one confirmation decision. State the decision, specimen, record or person, the time boundary and the responsible owner before interpreting any result.

Worked example: RT-PCR confirms exon skipping and quantifies residual normal transcript; the result is integrated under splicing guidance without double counting prediction. Put the starting evidence, applicable rule, intermediate decision, later observation and consequence on separate lines so that a fluent story cannot replace a reproducible pathway.

Evidence to retain: orthogonal method; primers; positive and negative controls; sequence; quantification; residual transcript; framework version; evidence dependencies Preserve provenance, dates, versions, identity checks, responsible people and intended use. If a necessary item is missing, label the gap and its effect instead of converting absence into reassurance.

Boundary and misconception: Confirmation of an RNA event does not automatically establish clinical pathogenicity, and using related assays as independent evidence can overstate weight. Test the strongest credible alternative explanation and name the new evidence that would change the conclusion. The pass condition is a bounded, reviewable claim, not the removal of uncertainty.

Evidence discipline: record the observation, version or time boundary that supports this chapter’s conclusion. Preserve the rejected alternative as well as the selected action. That makes a later review able to distinguish a changed world from an undocumented change of mind.

Changed-context transfer: Confirm the junction but discover it also occurs in controls and downgrade the interpretation. The method transfers only if the decision question and measurement meaning survive the change. If either changes, rebuild the comparison rather than copying the earlier threshold or weight.

Contents · Previous chapter · Next chapter

Limits and misconceptions

RNA is tissue and state dependent

An accessible tissue may not express the relevant gene, isoform or disease mechanism.

An outlier is not a diagnosis

Rarity in a reference distribution requires technical review, DNA linkage and clinical integration.

Negative evidence is coverage dependent

No detected event cannot exclude biology the specimen, library, depth or pipeline could not observe.

Confirmation validates an event, not every inference

An orthogonal assay can establish splicing or expression change while pathogenicity still depends on mechanism and other evidence.

Practise, verify and continue

Build an RNA-seq evidence map with diagnostic question, tissue, timing, identity, RNA integrity, library, depth, reference cohort, expression and splicing outputs, allelic imbalance, DNA link, confirmation, negative limits and reanalysis trigger.

Apply the method to long-read RNA sequencing. Preserve tissue, integrity, controls and DNA linkage, then add full-length transcript accuracy, isoform collapse, platform error and molecule-counting checks.

Practical evidence check

Before implementation, write a one-page evidence map with the decision, unit of analysis, version or time boundary, inputs, outcomes, uncertainty, authority and stop rule. Attach one worked case that passes and one that fails. A reviewer should be able to reproduce the reasoning without relying on the memory of the person who built the system.

Run one changed-context rehearsal before approval. Alter a mechanism rather than a cosmetic detail, then identify which calculation, safeguard or governance gate must change. Record any conclusion that does not transfer. This short rehearsal is often the fastest way to expose a hidden assumption before it becomes an operational dependency.

Related eduKate reading

Genome sequencing, gene panels and coverage gaps
Variant classification and conflicting evidence
Gene–disease validity and report correction
Long-read sequencing, phasing and confirmation

Authoritative sources and scope

ClinGen SVI recommendations for predicted and observed splicing impact
Clinical validation of RNA sequencing for Mendelian disorder diagnostics
Mapping RNA splicing across accessible and non-accessible tissues
Guidelines for clinical interpretation using RNA phenotypes
Clinical implementation of RNA sequencing for Mendelian disease diagnostics

These sources support the laboratory and evidence distinctions described here. They do not replace patient-specific diagnostic evaluation, genetic counselling, consent, laboratory validation, local regulation or a clinician’s interpretation. All worked cases are fictional. A functional or RNA result must be integrated with phenotype, inheritance and other evidence; it must not be used alone to diagnose or change care.

Back to contents · Return to the Genetics guide